Fixed Dose Combination Products [Design Issues]

posted by joyjac – Philippines, 2007-03-23 09:47 (7023 d 03:30 ago) – Posting: # 597
Views: 4,725

Dear colleagues,

Is it possible to apply scaled ABE on one active drug ingredient identified as a highly variable drug/drug product based on a previous study and on published literature, but make use of the conventional ABE approach for the other active drug component identified as not highly variable? Of course this will be stated a priori in the protocol. Your insight on this would be appreciated. Thanks.

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
120 visitors (0 registered, 120 guests [including 24 identified bots]).
Forum time: 14:18 CEST (Europe/Vienna)

I have never in my life learned anything
from any man who agreed with me.    Dudley Field Malone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5